3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 16,492 as of Wednesday, May 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,744 issues advancing vs. 1,239 declining with 163 unchanged.

The Drugs industry currently sits down 1.7% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Perrigo ( PRGO), down 8.4%, Vertex Pharmaceuticals ( VRTX), down 2.5%, Mylan ( MYL), down 2.1%, Alexion Pharmaceuticals ( ALXN), down 1.9% and Regeneron Pharmaceuticals ( REGN), down 1.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $1.50 (2.9%) to $52.40 on average volume. Thus far, 3.1 million shares of AbbVie exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $51.27-$52.75 after having opened the day at $52.38 as compared to the previous trading day's close of $50.91.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $82.0 billion and is part of the health care sector. Shares are down 3.6% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate AbbVie a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in stock price during the past year. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full AbbVie Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.55 (1.1%) to $50.13 on light volume. Thus far, 2.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $49.28-$50.44 after having opened the day at $49.65 as compared to the previous trading day's close of $49.58.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $43.1 billion and is part of the health care sector. Shares are up 23.7% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.96 (1.0%) to $100.47 on average volume. Thus far, 3.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $99.35-$100.56 after having opened the day at $99.85 as compared to the previous trading day's close of $99.51.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $282.9 billion and is part of the health care sector. Shares are up 8.7% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options